LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (OTCBB: IMUC) announced today that it has appointed Zvi Ram, M.D. and John Boockvar, M.D. to its Scientific Advisory Board. Dr. Ram is the Chairman of the Department of Neurosurgery at Tel Aviv Medical Center in Israel. Dr. John Boockvar is Co-Director of the Brain and Spinal Tumor Program at Weill Cornell Medical College. Dr. Ram and Dr. Boockvar join an accomplished Scientific Advisory Board that is expected to support the Company’s efforts later this year to commence a Phase II trial of ICT-107, the company’s dendritic cell based cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM). In the Phase I clinical study of ICT-107 in GBM, newly diagnosed patients who received the vaccine in addition to the standard of care of surgery, radiation and chemotherapy demonstrated a one year overall survival of 100 percent and a two year survival of 80 percent.
